Fig 2. MDA levels in the ventral prostate.
The effect of silodosin on MDA levels in the ventral prostate of the 18-week-old Wistar-Kyoto rat group (WKY), the 18-week-old SHR group (SHR) and the 18-week-old SHRs treated with silodosin at a daily dose of 100 μg/kg, p.o. (SHR+Sil100). Data are shown as mean ± SEM of eight separate determinations in each group. †: Significantly different with the WKY group; #: Significantly different with the SHR group (P < 0.05 is a level of significance).